LGM
CRSP icon

Logos Global Management’s CRISPR Therapeutics CRSP Stock Holding History

Logos Global Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-105,512
Closed -$4.47M – 52
2020
Q1 		$4.47M Buy
+105,512
New +$5.45M 1.7% 22

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Logos Global Management's CRSP Position: Q2 2020 in Review

Logos Global Management sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 105,512 shares — an estimated $4.47M sold.

Logos Global Management first reported a position in CRSP in Q1 2020 and held it in 1 quarter. The position peaked at $4.47M in Q1 2020. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Logos Global Management reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Logos Global Management sold 105,512 CRISPR Therapeutics shares in Q2 2020, an estimated $4.47M.
  • Logos Global Management first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 1 quarter.
  • Logos Global Management's CRISPR Therapeutics position peaked at $4.47M in Q1 2020.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Logos Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.